Precision Medicine in Oncology®

Martin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Barbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.

In 2011, the development of ipilimumab, a novel antibody targeting the CTLA-4 immune checkpoint, helped launch the modern era of anticancer immunotherapy.

Shubham Pant, MD, MBBS, discusses the investigation of adagrasib in the treatment of patients with KRAS G12C–mutated advanced solid tumors.

In this second episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, discuss some of the challenges faced with randomized control trials and 2 efforts underway that are slated to provide revelatory data on these assays.

In this third episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, discuss the LIBERATE study (NCT05383872) examining low-intensity focused ultrasound in patients with glioblastoma.

Michael Shusterman, MD, expands on the need for accurate early detection methods in solid tumors for which there aren’t proper surveillance tests, advantages of the unique methylation sequencing technique harnessed by this novel assay, and more.

In this first episode of OncChats: Examining the Promise of Multicancer Early Detection Tests, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Niloy Jewel J. Samadder, MD, provide an overview on multicancer early detection tests and the need for randomized clinical trials to further explore their use.

Lucia Masarova, MD, discusses the single-arm multicenter phase 2 EXCEED-ET trial of ropeginterferon alfa-2b-njft in adult patients with essential thrombocythemia.

The FDA has approved FoundationOne CDx for use as a companion diagnostic to determine patients with BRAF V600E–mutated metastatic colorectal cancer who may be candidates to receive encorafenib in combination with cetuximab.

In this second episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, discuss the success observed with low-intensity focused ultrasound in essential tremors and the hope for this approach in brain cancer.

James L. Gulley, MD, PhD, discusses a phase 1 trial of PRGN-2009 alone and in combination with bintrafusp alfa in patients with recurrent and/or metastatic HPV-associated cancers.

Gilteritinib led to a 48% reduction in disease recurrence for patients with FLT3-ITD–mutant acute myeloid leukemia and detectable minimal residual disease pre and post hematopoietic stem cell transplant compared with placebo, highlighting a role for treatment in this subgroup of patients.

Timothy I Shaw, PhD, discusses the genetic heterogeneity between paired primary and metastatic solid tumors, as well as the implications for neoantigen-based personalized vaccines in cancer care.

In this first episode of OncChats: Examining LIFU–Aided Liquid Biopsy in Glioblastoma, Manmeet Singh Ahluwalia, MD, MBA, FASCO, and Michael W. McDermott, MD, explain how low-intensity focused ultrasound works and the rationale for examining its use in cancer and other conditions.

When administered at doses of 90 μg/kg or higher, the novel DLL3-targeting T-cell engager, BI 764532, was found to have an acceptable toxicity profile and to elicit encouraging responses in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Experts in the field share the abstracts they found to be the most practice changing at this year’s ASCO Annual meeting.

The FDA has approved olaparib (Lynparza) plus abiraterone acetate (Zytiga) and prednisone or prednisolone for the treatment of patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an FDA-approved companion diagnostic test.

The combination of panitumumab and standard-of-care trifluridine-tipiracil rechallenge delivered a progression-free survival benefit vs trifluridine-tipiracil alone in the third-line setting in patients with refractory RAS wild-type metastatic colorectal cancer, meeting the primary end point of the phase 2 VELO trial.

Latinx patients with cancer had a low rate of tumor genomic profiling, partially due to structural and cultural barriers, according to findings from a qualitative study presented during the 5th Annual Regional SPEECH Conference and Retreat.

Japan’s Ministry of Health, Labour, and Welfare has approved quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation and as maintenance monotherapy in patients with newly diagnosed acute myeloid leukemia whose tumors harbor FLT3-ITD mutations.

CLDN18.2 has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer, gastroesophageal junction cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.

Ilyas Sahin, MD, details the preclinical findings from the study and highlighted how these data could help inform future studies for the treatment of patients with MDM2-overexpressing solid tumors.

Dana B Cardin, MD, MSCI, discusses the rationale for exploring KRAS as a therapeutic target in pancreatic cancer.

Although molecularly targeted therapies have transformed the treatment paradigm for NSCLC, the kaleidoscope of genomic alterations that affects subsets of patients is straining the limits of current diagnostic and clinical discovery approaches.